Glaukos Corp (N:GKOS)

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
See Regulatory Filings on SEC
Company Contact
Address: 1 GLAUKOS WAY
Tel: N/A
IR: See website
Key People
Thomas William Burns
Chairman of the Board, Chief Executive Officer
Joseph E. Gilliam
President, Chief Operating Officer
Alex R. Thurman
Chief Financial Officer, Senior Vice President
Tomas Navratil
Chief Development Officer
Business Overview
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
Financial Overview
For the three months ended 31 March 2024, Glaukos Corp revenues increased 16% to $85.6M. Net loss increased 18% to $40.8M. Revenues reflect Glaucoma segment increase of 20% to $67.2M, Corneal Health segment increase of 4% to $18.4M, United States segment increase of 16% to $57.7M, International segment increase of 15% to $27.9M. Higher net loss reflects Selling, general and administrative increase of 17% to $54.7M (expense), Interest and other expense.
Employees: 907 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $5,584M as of Mar 31, 2024
Annual revenue (TTM): $326.43M as of Mar 31, 2024
EBITDA (TTM): -$83.78M as of Mar 31, 2024
Net annual income (TTM): -$140.87M as of Mar 31, 2024
Free cash flow (TTM): -$75.17M as of Mar 31, 2024
Net Debt Last Fiscal Year: $80.55M as of Mar 31, 2024
Shares outstanding: 50,367,507 as of Apr 30, 2024
Index Membership: S&P 600 Small Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.